Beckman Coulter Life Sciences and IncellDx have announced a collaboration aimed at creating awareness for the oncology assays on the cytometry platform for European customers.
Beckman Coulter Life Sciences and IncellDx have announced, in a Nov. 20, 2019 press release, a collaboration aimed at creating awareness for the oncology assays on the cytometry platform for European customers.
Four cancer detection reagents were developed by IncellDx using Beckman Coulter’s instruments, under the partnership. The assays relate to lung and bladder cancers as well as human papillomavirus (HPV) cancers affecting the head, neck, and cervix.
“The new partnership brings the power of multi-parameter flow cytometry to molecular testing, improving workflow while delivering sensitive and highly reliable cell identification,” said Mario Koksch, vice-president and general manager, Beckman Coulter Life Sciences Cytometry Business Unit, in the press release. “In addition, the oncology menu of IncellDx adds a new dimension to Beckman Coulter instruments, such as the CytoFLEX Series, which positions our technology at the forefront of clinical research.”
Bruce Patterson, CEO and founder of IncellDx, commented, “In cancer research, it is essential to carry out quantification at the single cell level. Adding our single cell, simultaneous protein, mRNA, and cell cycle/DNA content assays to the technology behind Beckman Coulter Life Sciences flow cytometry instruments will open up a new era in understanding cancer biology.”
Source: Beckman Coulter
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.